Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Clinical Infectious Diseases

Volumn 45, Issue 11, 2007, Pages 1518-1521

  Brinkhof, Martin W G ^a   Egger, Matthias ^b   Boulle, Andrew ^c   May, Margaret ^d   Hosseinipour, Mina ^e   Sprinz, Eduardo ^f   Braitstein, Paula ^g   Dabis, François ^h   Reiss, Peter ⁱ   Bangsberg, David R ^j   Rickenbach, Martin ^k   Miro, Jose M ^l   Myer, Landon ^c   Mocroft, Amanda ^m   Nash, Denis ⁿ   Keiser, Olivia ^b   Pascoe, Margaret ^o   Van Der Borght, Stefaan ^p   Schechter, Mauro ^q   Brinkhof, Martin ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ISPM ^*

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e University of Carolina Project   (Malawi)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g MOI UNIVERSITY   (Kenya)

^h INSERM   (France)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Swiss HIV Cohort Study Data Center   (Switzerland)

^l UNIVERSITY OF BARCELONA   (Spain)

^m ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁿ Columbia University ^*  (United States)

^o Connaught Clinic ^*  (Zimbabwe)

^p Heineken International   (Netherlands)

^q FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS; ADULT; CD4 LYMPHOCYTE COUNT; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MIDDLE AGED;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INCOME; MALE; MIDDLE AGED; RISK FACTORS; TUBERCULOSIS;

EID: 38449116968     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522986     Document Type: Article

References (13)

1. World Health Organization. Towards universal access by 2010: how WHO is working with countries to scale-up HIV prevention, treatment, care and support. Available at http://www.who.int/hiv/toronto2006/towardsuniversalaccess.pdf. Accessed April 2007.
2. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-24.
3. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-24.
4. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-73.
5. Dabis F, Balestre E, Braitstein P, et al. Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005; 34:979-86.
6. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
7. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PloS Med 2007; 4:e120.
8. Girardi E, Sabin CA, D'Arminio MA, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772-82.
9. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113-24.
10. Tindo H, Cesar Cavalente S, Werneck-Barroso E. Gender differences in tuberculosis in Rio de Janeiro, Brasil. Int J Tuberc Lung Dis 2004;8:388-90.
11. Austin JF, Dick JM, Zwarenstein M. Gender disparity amongst TB suspects and new TB patients according to data recorded at the South African Institute of Medical Research laboratory for the Western Cape Region of South Africa. Int J Tuberc Lung Dis 2004; 8:435-9.
12. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-8.
13. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926-37.